Drugs / Anisodine Hydrobromide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07513233 | Apr → Aug 2026 overdue | ischemic stroke | Capital Medical University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05416476 | Oct 2023 → Oct 2025 | migraine with aura, migraine without aura | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anisodine Hydrobromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513233 ↗ |
| Known as | J3.145.635E | ChEMBL registry synonym — accepted as the source's own label CHEMBL4779850 ↗ |
| Modality | Small molecule | — CHEMBL4779850 ↗ |
| Route | Oral | “Anisodine Hydrobromide 1 mg oral tablet, twice times a day” NCT05416476 ↗ |